Adult Colchicine Prescription for Acute Gout Flare
For an acute gout flare in an adult, prescribe colchicine 0.6 mg tablets: take 2 tablets (1.2 mg) immediately at first sign of flare, followed by 1 tablet (0.6 mg) one hour later—total dose 1.8 mg over one hour. 1, 2
Prescription Details
Medication: Colchicine 0.6 mg tablets
Quantity: Dispense 3 tablets
Directions: Take 2 tablets by mouth immediately at first sign of gout flare, then take 1 tablet one hour later. Do not repeat for at least 3 days.
Refills: 0 (acute treatment only)
Dosing Rationale
This low-dose regimen is FDA-approved and strongly recommended by both the 2020 ACR 1 and 2017 ACP guidelines 3. The evidence is clear: low-dose colchicine (1.8 mg total over 1 hour) provides equivalent pain relief to high-dose regimens (4.8 mg over 6 hours) but with dramatically fewer gastrointestinal side effects 4. In the pivotal trial, 37.8% of patients achieved ≥50% pain reduction at 24 hours with low-dose colchicine versus only 15.5% with placebo, while adverse events were comparable to placebo 4.
High-dose colchicine causes diarrhea in 77% of patients (with 19% experiencing severe diarrhea) and vomiting in 17%, compared to 23% diarrhea and 0% vomiting with low-dose 4. The number needed to treat is 4 for benefit, while high-dose has a number needed to harm of 2 5.
Critical Precautions & Contraindications
Absolute Contraindications
Do NOT prescribe colchicine if the patient has:
- Severe renal impairment (eGFR <30 mL/min/1.73m²) AND is taking strong CYP3A4 or P-glycoprotein inhibitors 2
- Severe hepatic impairment AND is taking these same inhibitors 3
Mandatory Dose Adjustments
If patient is taking strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir, atazanavir, itraconazole, nelfinavir, saquinavir, telithromycin, indinavir, lopinavir/ritonavir, tipranavir/ritonavir, darunavir/ritonavir) 2:
- Reduce to: 0.6 mg × 1 dose, followed by 0.3 mg one hour later
- Do not repeat for at least 3 days
- Maximum daily dose: 0.6 mg if on chronic prophylaxis
If patient is taking moderate CYP3A4 inhibitors (diltiazem, verapamil, erythromycin, fluconazole, grapefruit juice) 2:
- Use: 1.2 mg × 1 dose only (do not give second 0.6 mg dose)
- Do not repeat for at least 3 days
If patient is taking P-glycoprotein inhibitors (cyclosporine, ranolazine) 2:
- Same reduction as strong CYP3A4 inhibitors: 0.6 mg followed by 0.3 mg one hour later
Renal Impairment Dosing
- Mild (eGFR 60-89): No adjustment needed 6
- Moderate (eGFR 30-59): Consider 0.48-0.5 mg dosing if available; standard 0.6 mg may cause toxicity 6
- Severe (eGFR 15-29): Reduce to 0.3 mg total dose; standard dosing causes supratherapeutic levels 36% of time 6
Patient Counseling Points
Timing is critical: Instruct patient to take medication at the very first sign of gout flare symptoms. Early administration significantly improves efficacy 1, 7. Consider "pills in pocket" strategy for patients who can recognize early flare symptoms 1.
Avoid grapefruit: No grapefruit or grapefruit juice while taking colchicine—increases drug levels and toxicity risk 2.
Expected side effects: Diarrhea (23%), nausea, or abdominal cramping are possible but much less common than with older high-dose regimens 4.
Do not exceed dose: Taking more than prescribed does not improve pain relief but dramatically increases side effects 3, 4.
Seek emergency care if: Severe diarrhea, vomiting, muscle weakness, or numbness develops 2.
Alternative First-Line Options
While colchicine is appropriate, corticosteroids should be considered first-line in patients without contraindications due to better safety profile and lower cost 3. Prednisolone 35 mg daily for 5 days is equally effective with fewer adverse effects than NSAIDs 3.
NSAIDs are also first-line but contraindicated in renal disease, heart failure, cirrhosis, or GI bleeding risk 3. No NSAID (including indomethacin) is superior to others 3.
The choice between colchicine, NSAIDs, and corticosteroids should be driven by patient comorbidities and contraindications 1, 3. All three are strongly recommended as equally effective first-line options by ACR 2020 1.
Common Pitfalls to Avoid
Do not prescribe old high-dose regimens (0.6 mg every hour until relief or diarrhea)—this is obsolete and dangerous 3, 4
Do not combine with statins without checking for drug interactions—while statins increase colchicine levels, recent data shows this doesn't consistently cause muscle toxicity, but monitor closely 8
Do not use in elderly with multiple comorbidities without dose adjustment—polypharmacy increases interaction risk 9
Do not prescribe refills for acute treatment—this is for single flare treatment only; if patient needs ongoing prophylaxis during urate-lowering therapy initiation, that requires separate prescription at 0.6 mg daily 1, 2
Do not start urate-lowering therapy during acute flare—wait until flare resolves, then initiate with prophylactic colchicine 0.6 mg daily for at least 6 months 1